Podderzhivayushchee lechenie u patsientov s gastroezofageal'noy reflyuksnoy bolezn'yu


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers the issues of secondary prevention of gastroesophageal reflux disease: effective initial and supportive therapy with proton pump inhibitors, the change in lifestyle and dietary preferences, and surgical treatment. From the perspective of evidence-based medicine, recommendations for lifestyle changes, the potentials for the application of constant and course supportive therapy, «day off» therapy and treatment «on demand» in patients with non-erosive and erosive variants of reflux disease are discussed.

Full Text

Restricted Access

References

  1. Аникина Н.Ю. Оценка эффективности и выбор различных режимов поддерживающей терапии больных гастроэзофагеальной рефлюксной болезнью 0-1-й степени тяжести. Дисс.. канд. мед. наук. М., 2009. 26 с.
  2. Диетология / Под ред. А.Ю. Барановского. СПб., 2012. 1024 с.
  3. AGA institute. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology. 2008; 135: 1383-91.
  4. Allaix M.E., Patti M.G. Current status of diagnosis and treatment of GERD in the US. Minerva Gastroenterol Dietol. 2013; 59: 41-48.
  5. Bytzer P., Morocutti A., Kennerly P., et al. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand. J. Gastroenterol. 2006; 41(10): 1132-40.
  6. Carlsson R. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastroenterol. 1998; 33(10): 1023-29.
  7. Carlsson R., Dent J., Watts R., et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur. J. Gastroenterol. Hepatol. 1998; 10(2): 119-24.
  8. Cibor D., Ciecko I., Owczareck D., et al. Optimal maintenance therapy in patients with non erosive reflux disease reporting mild reflux symptoms - a pilot study. Adv. Med. Sci. 2006; 51: 336-39.
  9. Clark C.S., Kraus B.B., Sinclair J., et al. Gastroesophageal reflux induced by exercise in healthy volunteers. JAMA. 1989; 261: 3599-601.
  10. Corley D.A., Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 2006; 101: 2619-28.
  11. De Giorgi F., Savarese M.F. Medical treatment of gastroesophageal reflux disease. Act. Otorhinolaryngol. Ital. 2006; 26(5): 276-80.
  12. Dent J., et al. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004; 53: 1-24.
  13. Donnellan C., Sharma N., Preston C., et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst. Rev. 2005: CD003245.
  14. El-Serag H.B., Satia J.A., Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005; 54: 11-17.
  15. Fass R., Delemos B., Nazareno L., et al. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a doubleblind, placebo-controlled, randomized study. Aliment Pharmacol Ther. 2010: 31(9): 950-60.
  16. Fausci A.S. Harrisons principles of internal medicine. NY.: Mc Graw Hill Medical, 2010. 2754 p.
  17. Festi D., Scaioli E., Baldi F., et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J. Gastroenterol. 2009; 15(14): 1690-701.
  18. Gardner J.D., Perdomo C., Sloan S. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol. Ther. 2002; 16(3): 455-64.
  19. Hampel H., Abraham N.S., El-Serag H.B. Metaanalysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann. Intern. Med. 2005; 137: 199-211.
  20. Haynes R.B., McDonald H., Garg A.X., et al. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. Ontario: McMaster University Medical Centre, 2008. 345 p.
  21. Hughes D.A., Bodger K., Bytzer P., et al. Economic analysis of ondemand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics. 2005; 23: 1031-41.
  22. Johnson D., Benjamin S., Vakil N., et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms. Am. J. Gastroenterol. 2001; 96: 27-34.
  23. Kahrilas P.J., Shaheen N.J., Vaezi M.F., et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008; 135: 1383-91.
  24. Katz P.O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am. J.Gastroenterol. 2013; 108: 308-28.
  25. Lee T.J., Fennerty M.B., Howden C.W. Systematic review: is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol. Ther. 2004; 20: 1241-51.
  26. McQuaid K.R., Laine L. Early heatburn relief with proton pump ingibitors: a systematic review and meta-analysis of clinical trials. Clin. Gastroenterol. Hepatol. 2005; 3(6) 553-63.
  27. Pace F., Annese V., Prada A. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig. Liver Dis. 2005: 37(10): 741-50.
  28. Pace F., Tonini M., Pallotta S. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand. Aliment. Pharmacol. Ther. 2007; 26(2): 195-204.
  29. Pilotto A., Di Mario F., Malfertheiner P., et al. Uper gastrointestinal diseases in the elderly. Eur. J. Gastroenterol. Hepatol. 1999; 11(7): 801-08.
  30. PrIndex (PRESCRIPTION INDEX) Monitoring of prescribing physicians. COMCON PHARMA. Available on: http://www.comcon-2.com/default.asp?trID=284. Russian (PrIndex (PRESCRIPTION INDEX) Мониторинг назначений лекарственных препаратов врачами. COMCON PHARMA. Доступно на: http://www.comcon-2.com/default.asp?trID=284).
  31. Reimer C., Sondergaard B., Hilsted L., et al. Proton pump inhibitor therapy induces acid related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009; 137: 80-87.
  32. Schindlbeck N.E., Heinrich C., Dendorfer A., et al. Influence of smoking and esophageal intubation on esophageal pH-metry. Gastroenterology. 1987; 92: 1994-97.
  33. Talley N.J., Armstrong D., Junghard O., et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment. Pharmacol. Ther. 2006; 24(2): 371-76.
  34. Tao J., Xiao Y.L., Chen M.H., et al. Changes of intercellular spaces of esophageal epithelium in patients with gastroesophageal reflux disease before and after esomeprazole treatment. Zhonghua Yi Xue Za Zhi. 2007; 87(6): 392-95.
  35. Vasiliadis K.V., Viazis N., Vlachogiannakos J. et al. Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system. Am. J. Gastroenterol. 2010; 105(2): 308-13.
  36. Venkataraman J., Krishnan A. Long-term medical management of gastro-esophageal reflux disease: how long and when to consider surgery? Trop Gastroenterol. 2012; 33: 21-32.
  37. Zheng Z., Nordenstedt H., Pedersen N.L., et al. Lifestyle factors and risk for symptomatic gastroesophageal reflux in monozygotic twins. Gastroenterology. 2007; 132: 87-95.
  38. Barnett J.L., Robinson M. Optimizing Acid-Suppression therapy. Manag. Care. 2001; 10(Suppl. 10): 17-21.
  39. Robinson M., et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis, Aliment. Pharmacol. Ther. 2002: 16: 445-54.
  40. Kahrilas P.J., et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reux oesophagitis patients: a randomized controlled trial. Aliment. Pharmacol. Ther. 2000; 14: 1249-58.
  41. Labenz J., et al. A randomized comparative study of esomeprazole 40 mg versus panto-prazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment. Pharmacol. Ther. 2005; 21: 739-46.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies